Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 231

Results For "PLI"

2779 News Found

Ascletis expands ritonavir oral tablet production
Biotech | January 03, 2022

Ascletis expands ritonavir oral tablet production

ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection


Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID
Public Health | January 03, 2022

Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID

The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records


Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry
News | December 30, 2021

Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry

Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness


Merck awarded €121 million contract for flow membrane production facility in Wisconsin, USA
Diagnostic Center | December 30, 2021

Merck awarded €121 million contract for flow membrane production facility in Wisconsin, USA

The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness


Granules receives ANDA approval for amphetamine mixed salts
Drug Approval | December 30, 2021

Granules receives ANDA approval for amphetamine mixed salts

The current annual U.S. market for amphetamine mixed salts, USP 1.25mg, 1.875mg, 2.5mg, 3.125mg, 3.75mg, 5mg, 7.5mg immediate release tablets strengths is approximately US $ 335 million, according to MAT, Oct 2021 IQVIA/IMS Health


Strides to market molnupiravir under the brand name Stripiravir
Drug Approval | December 28, 2021

Strides to market molnupiravir under the brand name Stripiravir

Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2


Expectations and predictions for 2022
Opinion | December 28, 2021

Expectations and predictions for 2022

In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc


Granules Inc., receives ANDA approval for prazosin hydrochloride
Drug Approval | December 28, 2021

Granules Inc., receives ANDA approval for prazosin hydrochloride

The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health


Cipla receives EUA for Cipmolnu
Drug Approval | December 28, 2021

Cipla receives EUA for Cipmolnu

The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use


Sun Pharma receives DCGI approval for Molxvir in India
Drug Approval | December 28, 2021

Sun Pharma receives DCGI approval for Molxvir in India

The product is expected to be available in a week’s time